Government-Owned Inventions; Availability for Licensing, 25307-25308 [2015-10275]

Download as PDF Federal Register / Vol. 80, No. 85 / Monday, May 4, 2015 / Notices and Resources Research, National Institutes of Health, HHS) Dated: April 28, 2015. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–10271 Filed 5–1–15; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Determining the Genetic and Diagnostic Markers of Acute Renal Allograft Rejection (K24). Date: May 26, 2015. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications Place: National Institutes of Health, 5601 Fisher Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC9823, Bethesda, MD 20892–9823, (240) 669–5068, zhuqing.li@nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Innovative Technologies for Differential Diagnosis of Acute Febrile Illnesses (R21/R33). Date: May 27, 2015. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fisher Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Eleazar Cohen, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 6700 B Rockledge Drive, Room 3129, Bethesda, MD 20892, 301–435–3564, ec17w@nih.gov. 19:40 May 01, 2015 Jkt 235001 Dated: April 28, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: April 28, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–10278 Filed 5–1–15; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2015–10274 Filed 5–1–15; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) 25307 DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institute of Nursing Research; Notice of Closed Meeting National Institute On Aging; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel Performance Measures of Multiple Chronic Conditions (MCC). Date: May 28, 2015. Time: 12:00 p.m. to 2:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Isis S. Mikhail, MD, MPH, DRPH, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7704, mikhaili@mail.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel Polyphenols and Alzheimer’s Disease. Date: June 11, 2015. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Isis S. Mikhail, MD, MPH, DRPH, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7704, mikhaili@mail.nih.gov. PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Nursing Research Initial Review Group. Date: June 18–19, 2015. Time: 8:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Weiqun Li, MD, Scientific Review Officer, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Suite 703, Bethesda, MD 20892, (301) 402–5807, wli@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS) Dated: April 28, 2015. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–10270 Filed 5–1–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. E:\FR\FM\04MYN1.SGM 04MYN1 25308 ACTION: Federal Register / Vol. 80, No. 85 / Monday, May 4, 2015 / Notices Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer Description of Technology: The invention relates to novel Furoquinolinediones derivatives and their ability to inhibit the enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2), and therefore to serve as anticancer agents. Furthermore, these compounds can be used in combination with topoisomerase II (Top2) inhibitors, such as etoposide or doxorubicin, to more effectively kill cancer cells in a synergistic fashion. Pharmaceutical compositions containing these novel Furoquinolinediones and methods of treatment comprising administering of such compositions are disclosed in the invention. Potential Commercial Applications: Furoquinolinediones derivatives can potentially be utilized for cancer treatment either as stand alone or in combination with other drugs such as Top2 inhibitors. Competitive Advantages: Combination therapies based on the association of a TDP2 and a Top2 inhibitor because of their synergistic effect should allow the decrease of the effective dosage. Their therapeutic benefit should be observed at non-toxic concentrations for normal cells as it has already been demonstrated for PARP inhibitors in BRCA-deficient tumors. Development Stage: In vitro data available VerDate Sep<11>2014 19:40 May 01, 2015 Jkt 235001 Inventors: Christophe R. Marchand, Likun An, Yves G. Pommier (all of NCI) Intellectual Property: HHS Reference No. E–275–2014/0—US Provisional Application No. 62/100,968 filed January 8, 2015 Licensing Contact: Kevin Chang, Ph.D.; 301–435–5018; changke@ mail.nih.gov Transgenic Mouse Model of Human Open Angle Glaucoma Description of Technology: Glaucoma is a group of chronic neurodegenerative disorders, which is characterized by progressive loss of retinal ganglion cells (RGC) and results in irreversible damage to optic nerve and thereby loss of vision. Primary open angle glaucoma (POAG) is the most common form of glaucoma; mutations in MYOC gene are the most common genetically defined cause of POAG. As such, MYOC transgenic mouse models are very useful to study MYOC-associated glaucoma and to develop therapies to treat these diseases. The NIH inventors generated a new MYOC mouse model carrying a mutant human MYOC (Y437H) gene. The Y437H mutation is associated with a severe form of glaucoma among the identified MYOC mutations. Potential Commercial Applications: • Research tools • Drug development for glaucoma Competitive Advantages: The new transgenic mouse model carries a mutation associated with a severe form of glaucoma in humans. Development Stage: Prototype. Inventors: Stanislav Tomarev (NEI), Yu Zhou (former NEI), Oleg Grinchuk (former NEI). Publications: 1. Zhou Y, et al. Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. Invest Ophthalmol Vis Sci. 2008 May;49(5):1932–9. [PMID 18436825] 2. Joe MK, Tomarev SI. Expression of myocilin mutants sensitizes cells to oxidative stress-induced apoptosis: implication for glaucoma pathogenesis. Am J Pathol. 2010 Jun;176(6):2880–90. [PMID 20382707] 3. Chou TH, et al. Transgenic mice expressing mutated Tyr437His human myocilin develop progressive loss ofretinal ganglion cell electrical responsiveness and axonopathy with normal IOP. Invest Ophthalmol Vis Sci. 2014 Aug 14;55(9):5602–9. [PMID 25125600] Intellectual Property: HHS Reference No. E–091–2015/0—Research Tool. Patent protection is not being pursued for this technology. Licensing Contact: Tedd Fenn; 424– 297–0336; tedd.fenn@nih.gov. PO 00000 Frm 00035 Fmt 4703 Sfmt 9990 Dated: April 27, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2015–10275 Filed 5–1–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–12– 095: Special Review. Date: May 6, 2015. Time: 11:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Angela Y. Ng, Ph.D., MBA, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6200, MSC 7804, Bethesda, MD 20892, 301–435– 1715, nga@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: April 28, 2015. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–10272 Filed 5–1–15; 8:45 am] BILLING CODE 4140–01P E:\FR\FM\04MYN1.SGM 04MYN1

Agencies

[Federal Register Volume 80, Number 85 (Monday, May 4, 2015)]
[Notices]
[Pages 25307-25308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-10275]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

[[Page 25308]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use 
to Treat Cancer

    Description of Technology: The invention relates to novel 
Furoquinolinediones derivatives and their ability to inhibit the enzyme 
tyrosyl-DNA phosphodiesterase 2 (TDP2), and therefore to serve as anti-
cancer agents. Furthermore, these compounds can be used in combination 
with topoisomerase II (Top2) inhibitors, such as etoposide or 
doxorubicin, to more effectively kill cancer cells in a synergistic 
fashion.
    Pharmaceutical compositions containing these novel 
Furoquinolinediones and methods of treatment comprising administering 
of such compositions are disclosed in the invention.
    Potential Commercial Applications: Furoquinolinediones derivatives 
can potentially be utilized for cancer treatment either as stand alone 
or in combination with other drugs such as Top2 inhibitors.
    Competitive Advantages: Combination therapies based on the 
association of a TDP2 and a Top2 inhibitor because of their synergistic 
effect should allow the decrease of the effective dosage. Their 
therapeutic benefit should be observed at non-toxic concentrations for 
normal cells as it has already been demonstrated for PARP inhibitors in 
BRCA-deficient tumors.
    Development Stage: In vitro data available
    Inventors: Christophe R. Marchand, Likun An, Yves G. Pommier (all 
of NCI)
    Intellectual Property: HHS Reference No. E-275-2014/0--US 
Provisional Application No. 62/100,968 filed January 8, 2015
    Licensing Contact: Kevin Chang, Ph.D.; 301-435-5018; 
changke@mail.nih.gov

Transgenic Mouse Model of Human Open Angle Glaucoma

    Description of Technology: Glaucoma is a group of chronic 
neurodegenerative disorders, which is characterized by progressive loss 
of retinal ganglion cells (RGC) and results in irreversible damage to 
optic nerve and thereby loss of vision. Primary open angle glaucoma 
(POAG) is the most common form of glaucoma; mutations in MYOC gene are 
the most common genetically defined cause of POAG. As such, MYOC 
transgenic mouse models are very useful to study MYOC-associated 
glaucoma and to develop therapies to treat these diseases.
    The NIH inventors generated a new MYOC mouse model carrying a 
mutant human MYOC (Y437H) gene. The Y437H mutation is associated with a 
severe form of glaucoma among the identified MYOC mutations.
    Potential Commercial Applications:
     Research tools
     Drug development for glaucoma
    Competitive Advantages: The new transgenic mouse model carries a 
mutation associated with a severe form of glaucoma in humans.
    Development Stage: Prototype.
    Inventors: Stanislav Tomarev (NEI), Yu Zhou (former NEI), Oleg 
Grinchuk (former NEI).
    Publications:

    1. Zhou Y, et al. Transgenic mice expressing the Tyr437His 
mutant of human myocilin protein develop glaucoma. Invest Ophthalmol 
Vis Sci. 2008 May;49(5):1932-9. [PMID 18436825]
    2. Joe MK, Tomarev SI. Expression of myocilin mutants sensitizes 
cells to oxidative stress-induced apoptosis: implication for 
glaucoma pathogenesis. Am J Pathol. 2010 Jun;176(6):2880-90. [PMID 
20382707]
    3. Chou TH, et al. Transgenic mice expressing mutated Tyr437His 
human myocilin develop progressive loss ofretinal ganglion cell 
electrical responsiveness and axonopathy with normal IOP. Invest 
Ophthalmol Vis Sci. 2014 Aug 14;55(9):5602-9. [PMID 25125600]

    Intellectual Property: HHS Reference No. E-091-2015/0--Research 
Tool. Patent protection is not being pursued for this technology.
    Licensing Contact: Tedd Fenn; 424-297-0336; tedd.fenn@nih.gov.

    Dated: April 27, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-10275 Filed 5-1-15; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.